Dr Ian Smith (Co-founder, Director and Chief Medical Officer) and Chris Dodd (Chief Commercial Officer) recently spoke to Jo Shorthouse at In Vivo to discuss the practicalities and reality of running clinical trial sites as a business, the efficiencies found with the SMO model, the challenge of patient recruitment as well as the decentralized and hybridized trial model. To listen to the …
The independent Site Management Organisations (SMOs) which run clinical trials on behalf of the pharmaceutical industry continue to expand not only the number of trials being brought to the UK but also the number of patients enrolled.
New data show that the site management model reduces start-up times for a Phase II or Phase III clinical trial by up to nine months compared to UK public sites, representing billions in savings Panthera identifies likely patients seven months before public sector sites start planning their recruitment campaigns. The loss of nine months patent …
Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion across the UK and Western Europe Panthera Biosciences (Panthera) has secured £10 million of investment from BGF and Gresham House Ventures, the latter investing on behalf of the Baronsmead VCTs. This investment will allow Panthera to further grow its network of dedicated …
Panthera have formed a partnership with Preston North End Football Club Community Trust. The team at Panthera attended the PNE vs Birmingham City game on the 15th of January promoting clinical trials. Fans who visited the Panthera van on game day also learnt more about additional clinical trials, such as those aimed at combating Osteoarthritis and Cardiovascular …
